Targeting abnormal airway vascularity as a therapeutical strategy in asthma

Respirology

Volumn 15, Issue 3, 2010, Pages 459-471

  Park, Hee Sun ^a   Kim, Sun Young ^a   Kim, So Ri ^b   Lee, Yong Chul ^b  

^a Chungnam National University   (South Korea)

^b Chonbuk National University Medical School   (South Korea)

Author keywords

Angiogenesis; Asthma; Hyperpermeability; Vascular remodelling; Vasodilatation

Indexed keywords

ANGIOGENIN; ANGIOPOIETIN; AXITINIB; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BEVACIZUMAB; CORTICOSTEROID DERIVATIVE; CYCLOOXYGENASE 2 INHIBITOR; ENDOTHELIN 1; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; GELATINASE A; GELATINASE B; HISTAMINE; PEGAPTANIB; PROSTAGLANDIN E2; RANIBIZUMAB; SORAFENIB; SUNITINIB; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA1; VANDETANIB; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VATALANIB;

ANGIOGENESIS; ASTHMA; HUMAN; LUNG CIRCULATION; MAST CELL; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; REVIEW;

ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHI; HUMANS; MICROCIRCULATION; NEOVASCULARIZATION, PATHOLOGIC; VASODILATION;

EID: 77950285010     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2010.01724.x     Document Type: Review

References (172)

1. Kanazawa H, Asai K, Hirata K et al. Vasculae involvement in exercise-induced airway narrowing in patients with bronchial asthma. Chest 2002 122 : 166 170.
2. Nocker RE, Weller FR, Out TA et al. A double-blind study on the effect of inhaled corticosteroids on plasma protein exudation in asthma. Am. J. Respir. Crit. Care Med. 1999 159 : 1499 1505.
3. Chetta A, Zanini A, Foresi A et al. Vascular component of airway remodeling in asthma is reduced by high dose of fluticasone. Am. J. Respir. Crit. Care Med. 2003 167 : 751 757.
4. Li X, Wilson JW. Increased vascularity of the bronchial mucosa in mild asthma. Am. J. Respir. Crit. Care Med. 1997 156 : 229 233.
5. Orsida BE, Li X, Hickey B et al. Vascularity in asthmatic airways: relation to inhaled steroid dose. Thorax 1999 54 : 289 295.
6. Vrugt B, Wilson S, Bron A et al. Bronchial angiogenesis in severe glucocorticoid-dependent asthma. Eur. Respir. J. 2000 15 : 1014 1021.
7. Salvato G. Quantitative and morphological analysis of the vascular bed in bronchial biopsy specimens from asthmatic and non-asthmatic subjects. Thorax 2001 56 : 902 906.
8. Deal EC Jr., McFadden ER Jr., Ingram RH et al. Role of respiratory heat exchange in production of exercise-induced asthma. J. Appl. Physiol. 1979 46 : 467 475.
9. McFadden ER Jr., Gilbert IA. Exercise-induced asthma. N. Engl. J. Med. 1994 330 : 1362 1367.
10. Cabanes L, Costes F, Weber S et al. Improvement in exercise performance by inhalation of methoxamine in patients with impaired left ventricular function (comment). N. Engl. J. Med. 1992 326 : 1661 1665.
11. Csete ME, Abraham WM, Wanner A. Vasomotion influences airflow in peripheral airways. Am. Rev. Respir. Dis. 1990 141 : 1409 1413.
12. Blosser S, Mitzner W, Wagner EM. Effects of increased bronchial blood flow on airway morphometry, resistance, and reactivity. J. Appl. Physiol. 1994 76 : 1624 1629.
13. Long WM, Yerger LD, Martinez H et al. Modification of bronchial blood flow during allergic airway responses. J. Appl. Physiol. 1988 65 : 272 282.
14. Wanner A. Circulation of the airway mucosa. J. Appl. Physiol. 1989 67 : 917 925.
15. Webber SE, Salonen RO, Corfield DR et al. Effects of non-neuroal mediators and allergen on tracheobronchial blood flow. Eur. Respir. J. 1990 12 : 638s 44s.
16. Barnes PJ. Pathophysiology of asthma. Br. J. Clin. Pharmacol. 1996 42 : 3 10.
17. Gallagher SJ, Shank JA, Bochner BS et al. Methods to track leukocyte and erythrocyte transit through the bronchial vasculature in sheep. J. Immunol. Methods 2002 271 : 89 97.
18. Lim LH, Bochner BS, Wagner EM. Leukocyte recruitment in the airways: an intravital microscopic study of rat tracheal microcirculation. Am. J. Physiol. Lung Cell. Mol. Physiol. 2002 282 : L959 67.
19. Kelly L, Kolbe J, Mitzner W et al. Bronchial blood flow affects recovery from constriction in dog lung periphery. J. Appl. Physiol. 1986 60 : 1954 1959.
20. Csete ME, Chediak AD, Abraham WM et al. Airway blood flow modifies allergic airway smooth muscle contraction. Am. Rev. Respir. Dis. 1991 144 : 59 63.
21. Dvorak HF, Brown LF, Detmar M et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 1995 146 : 1029 1039.
22. Nagy JA, Benjamin L, Zeng H et al. Vascular permeability, vascular hyperpermeability and angiogenesis. Angiogenesis 2008 11 : 109 119.
23. Foster WM, Langenback EG, Bergofsky EH. Lung mucociliary function in man: interdependence of bronchial and tracheal mucus transport velocities with lung clearance in bronchial asthma and healthy subjects. Ann. Occup. Hyg. 1982 26 : 227 244.
24. Charan NB, Baile EM, Pare PD. Bronchial vascular congestion and angiogenesis. Eur. Respir. J. 1997 10 : 1173 1180.
25. Hashimoto M, Tanaka H, Abe S. Quantitative analysis of bronchial wall vascularity in the medium and small airways of patients with asthma and COPD. Chest 2005 127 : 965 972.
26. Redington AE, Roche WR, Madden J et al. Basic fibroblast growth factor in asthma: measurement in bronchoalveolar lavage fluid basally and following allergen challenge. J. Allergy Clin. Immunol. 2001 107 : 284 287.
27. Hoshino M, Nakamura Y, Hamid QA. Gene expression of vascular endothelial growth factor and its receptors and angiogenesis in bronchial asthma. J. Allergy Clin. Immunol. 2001 107 : 1034 1038.
28. McKenzie AW, Stoughton RB. Method for comparing percutaneous absorption of steroids. Arch. Dermotol. 1962 86 : 608 610.
29. Walters EH, Soltani A, Reid DW et al. Vascular remodeling in asthma. Curr. Opin. Allergy Clin. Immunol. 2008 8 : 39 43.
30. Hoshino M, Takahashi M, Aoike N. Expression of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin immunoreactivity in asthmatic airways and its relationship to angiogenesis. J. Allergy Clin. Immunol. 2001 107 : 295 301.
31. Thurston G, Murphy TJ, Baluk P et al. Angiogenesis in mice with chronic airway inflammation: strain-dependent differences. Am. J. Pathol. 1998 153 : 1099 1112.
32. Chetta A, Zanini A, Foresi A et al. Vascular endothelial growth factor up-regulation and bronchial wall remodelling in asthma. Clin. Exp. Allergy 2005 35 : 1437 1442.
33. Feltis BN, Wignarajah D, Zheng L et al. Increased vascular endothelial growth factor and receptors: relationship to angiogenesis in asthma. Am. J. Respir. Crit. Care Med. 2006 173 : 1201 1207.
34. Barbato A, Turato G, Baraldo S et al. Epithelial damage and angiogenesis in the airways of children with asthma. Am. J. Respir. Crit. Care Med. 2006 174 : 975 981.
35. McDonald DM. Angiogenesis and remodeling of airway vasculature in chronic inflammation. Am. J. Respir. Crit. Care Med. 2001 164 : S39 45.
36. Mitzner W, Wagner EM. Vascular remodeling in the circulations of the lung. J. Appl. Physiol. 2004 97 : 1999 2004.
37. Abdel-Rahman AM, El-Sahrigy SA, Bakr SI. A comparative study of two angiogenic factors. Vascular endothelial growth factor and angiogenin in induced sputum from asthmatic children in acute attack. Chest 2006 129 : 266 271.
38. Bradding P, Holgate ST. Immunopathology and human mast cell cytokines. Crit. Rev. Oncol. Hematol. 1999 31 : 119 133.
39. Seo KH, Lee HS, Jung B et al. Estrogen enhances angiogenesis through a pathway involving platelet-activating factor-mediated nuclear factor-kappaB activation. Cancer Res. 2004 64 : 6482 6488.
40. Deo DD, Axelrad TW, Robert EG et al. Phosphorylation of STAT-3 in response to basic fibroblast growth factor occurs through a mechanism involving platelet-activating factor, JAK-2, and Src in human umbilical vein endothelial cells. Evidence for a dual kinase mechanism. J. Biol. Chem. 2002 277 : 21237 21245.
41. BenEzra D. Neovasculogenic ability of prostaglandins, growth factors, and synthetic chemoattractants. Am. J. Ophthalmol. 1978 86 : 455 461.
42. Form DM, Auerbach R. PGE2 and angiogenesis. Proc. Soc. Exp. Biol. Med. 1983 172 : 214 218.
43. Stjernschantz J, Nilsson SF, Astin M. Vasodynamic and angiogenic effects of eicosanoids in the eye. Prog. Clin. Biol. Res. 1989 312 : 155 170.
44. Venable ME, Zimmerman GA, McIntyre TM et al. Platelet-activating factor: a phospholipid autacoids with diverse actions. J. Lipid. Res. 1993 34 : 691 702.
45. Andrade SP, Vieira LB, Bakhle YS et al. Effects of platelet activating factor (PAF) and other vasoconstrictors on a model of angiogenesis in the mouse. Int. J. Exp. Pathol. 1992 73 : 503 513.
46. Jackson JR, Bolognese B, Mangar CA et al. The role of platelet activating factor and other lipid mediators in inflammatory angiogenesis. Biochim. Biophys. Acta 1998 1392 : 145 152.
47. Axelrad TW, Deo DD, Ottino P et al. Platelet-activating factor (PAF) induces activation of matrix metalloproteinase 2 activity and vascular endothelial cell invasion and migration. FASEB J. 2004 18 : 568 570.
48. Busse WW. Leukotrienes and inflammation. Am. J. Respir. Crit. Care Med. 1998 157 : S210 13.
49. Mendes ES, Campos MA, Hurtado A et al. Effect of montelukast and fluticasone propionate on airway mucosal blood flow in asthma. Am. J. Respir. Crit. Care Med. 2004 169 : 1131 1134.
50. Lee KS, Kim SR, Park HS et al. Cysteinyl leukotriene receptor antagonist regulates vascular permeability by reducing vascular endothelial growth factor expression. J. Allergy Clin. Immunol. 2004 114 : 1093 1099.
51. Boqatcheva NV, Sergeeva MG, Dedek SM et al. Arachidonic acid cascade in endothelial pathobiology. Microvasc. Res. 2005 69 : 107 127.
52. Jain RK. Molecular regulation of vessel maturation. Nat. Med. 2003 9 : 685 693.
53. Bischoff J. Approaches to studying cell adhesion molecules in angiogenesis. Trends Cell. Biol. 1995 5 : 69 74.
54. Lee KS, Lee KY, Kim SR et al. Blockade of airway inflammation and hyper-responsiveness by an angiopoietin-1 variant, COMP-Ang1. Exp. Mol. Med. 2007 39 : 733 745.
55. Lee KS, Kim SR, Park SJ et al. Peroxisome proliferator activated receptor-γ modulates reactive oxygen species generation and activation of nuclear factor-Bκ and hypoxia-inducible factor 1α in allergic airway disease of mice. J. Allergy Clin. Immunol. 2006 118 : 120 127.
56. Lee KS, Kim SR, Park SJ et al. Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) reduces vascular endothelial growth factor expression in allergen-induced airway inflammation. Mol. Pharm. 2006 69 : 1829 1839.
57. Cavallaro U, Leibner S, Dejana E. Endothelial cadherins and tumor angiogenesis. Exp. Cell. Res. 2006 312 : 659 667.
58. Osborn L, Hession C, Tizard R et al. Direct expression cloning of vascular cell adhesion molecule 1, a cytokine induced endothelial protein that binds to lymphocytes. Cell 1989 59 : 1203 1211.
59. Polte T, Newman W, Raghunathan G et al. Structural and functional studies of full-length vascular cell adhesion molecule-1: internal duplication and homology to several adhesion proteins. DNA Cell. Biol. 1991 10 : 349 357.
60. Li L, Wartchow CA, Danthi SN et al. A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles. Int. J. Radiat. Oncol. Biol. Phys. 2004 58 : 1215 1227.
61. Nisato RE, Tille JC, Jonczyk A et al. alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro. Angiogenesis 2003 6 : 105 119.
62. Brooks PC, Clark RAF, Cheresh DA. Requirement of vascular integrin αvβ3 for angiogenesis. Science 1994 264 : 569 571.
63. Brooks PC, Montgomery AMP, Rosenfeld M et al. Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogemc blood vessels. Cell 1994 79 : 1157 1164.
64. Brooks PC, Stromblad S, Klemke R et al. Antiintegrin αvβ3 blocks human breast cancer growth and angiogenesis in human skin. J. Clin. Invest. 1995 96 : 1815 1822.
65. Drake J, Cheresh DA, Little CD. An antagonist of integrin αvβ3 prevents maturation of blood vessels during embryonic neovascularization. J. Cell. Sci. 1995 108 : 2655 2661.
66. Ruoslahti E. Specialization of tumour vasculature. Nat. Rev. Cancer 2002 2 : 83 90.
67. 1 blocks antigen-induced airway responses and inflammation in experimental asthma in sheep. Am. J. Respir. Crit. Care Med. 2000 162 : 603 611.
68. Thompson EE, Pan L, Ostrovnaya I et al. Integrin 3 genotype influences asthma and allergy phenotypes in the first 6 years of life. J. Allergy Clin. Immunol. 2007 119 : 1423 1429.
69. Barthel SR, Johansson MW, McNamee DM et al. Roles of integrin activation in eosinophil function and the eosinophilic inflammation of asthma. J. Leukoc. Biol. 2008 83 : 1 12.
70. Johansson MW, Kelly EAB, Busse WW et al. Up-regulation and activation of eosinophil integrins in blood and airway after segmental lung antigen challenge. J. Immunol. 2008 180 : 7622 7635.
71. Calabrese C, Bocchino V, Vatrella A et al. Evidence of angiogenesis in bronchial biopsies of smokers with and without airway obstruction. Respir. Med. 2006 100 : 1415 1422.
72. Bocchino V, Bertorelli G, Zanini A et al. Integrin αvβ3 is increased in the airways of atopic asthmatic patients [abstract]. Am. J. Respir. Crit. Care Med. 2001 163 : A785.
73. Coussens LM, Tinkle CL, Hanahan D et al. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000 103 : 481 490.
74. Zhou Z, Apte SS, Soininen R et al. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc. Natl. Acad. Sci. USA 2000 97 : 4052 4057.
75. Bergers G, Brekken R, McMahon G et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2000 2 : 737 744.
76. Lee KS, Min KH, Kim SR et al. Vascular endothelial growth factor modulates matrix metalloproteinase-9 expression in asthma. Am. J. Respir. Crit. Care Med. 2006 174 : 161 170.
77. Asai K, Kanazawa H, Otani K et al. Imbalance between vascular endothelial growth factor and endostatin levels in induced sputum from asthmatic subjects. J. Allergy Clin. Immunol. 2002 110 : 571 575.
78. Kanazawa H, Hirata K, Yoshikawa J. Involvement of vascular endothelial growth factor in exercise induced bronchoconstriction in asthmatic patients. Thorax 2002 57 : 885 888.
79. Lee YC, Lee HK. Vascular endothelial growth factor in patients with acute asthma. J. Allergy Clin. Immunol. 2001 107 : 1106 1108.
80. Senger DR, Galli SJ, Dvorak AM et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983 219 : 983 985.
81. H2-mediated sensitization and inflammation in the lung. Nat. Med. 2004 10 : 1095 1103.
82. Baluk P, Lee CG, Link H et al. Regulated angiogenesis and vascular regression in mice overexpressing vascular endothelial growth factor in airways. Am. J. Pathol. 2004 165 : 1071 1085.
83. Suzaki Y, Hamada K, Sho M et al. A potent antiangiogenic factor, endostatin prevents the development of asthma in a murine model. J. Allergy Clin. Immunol. 2005 116 : 1220 1227.
84. Yancopoulos GD, Davis S, Gale NW et al. Vascular-specific growth factors and blood vessel formation. Nature 2000 407 : 242 248.
85. Zagzag D, Amirnovin R, Greco MA et al. Vascular apoptosis and involution in gliomas precede neovascularization: a novel concept for glioma growth and angiogenesis. Lab. Invest. 2000 80 : 837 849.
86. Thurston G, Rudge JS, Ioffe E et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat. Med. 2000 6 : 460 463.
87. Kim I, Moon SO, Park SK et al. Angiopoietin-1 reduces VEGF-stimulated leukocyte adhesion to endothelial cells by reducing ICAM-1, VCAM-1, and E-selectin expression. Circ. Res. 2001 89 : 477 479.
88. Pizurki L, Zhou Z, Glynos K et al. Angiopoietin-1 inhibits endothelial permeability, neutrophil adherence and IL-8 production. Br. J. Pharmacol. 2003 139 : 329 336.
89. Gamble J, Drew J, Tresize L et al. Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cells junctions. Circ. Res. 2000 87 : 603 607.
90. Maisonpierre PC, Suri C, Jones PF et al. Angiopoietin-2, a natural antagonist for Tie 2 that disrupts in vivo angiogenesis. Science 1997 277 : 55 60.
91. Simoes DC, Vassilakopoulos T, Toumpanakis D et al. Angiopoietin-1 protects against airway inflammation and hyperreactivity in asthma. Am. J. Respir. Crit. Care Med. 2008 177 : 1314 1321.
92. Kanazawa H, Nomura S, Asai K. Roles of angiopoietin-1 and angiopoietin-2 on airway microvascular permeability in asthmatic patients. Chest 2007 131 : 1035 1041.
93. Kanazawa H, Tochino Y, Asai K. Angiopoietin-2 as a contributing factor of exercise-induced bronchoconstriction in asthmatic patients receiving inhaled corticosteroid therapy. J. Allergy Clin. Immunol. 2008 121 : 390 395.
94. Borish L, Rosenwasser LJ. Cytokines in allergic inflammation. In : Adkinson NF Jr., Yunginger JW, Busse WW et al. (eds) Middleton's Allergy Principles & Practice, 6th edn. Mosby 2005, Philadelphia, PA, USA.
95. Fagan KA, McMurtry IF, Rodman DM. Role of endothelin-1 in lung disease. Respir. Res. 2001 2 : 90 101.
96. Chalmers GW, Little SA, Patel KR et al. Endothelin-1 induced bronchoconstriction in asthma. Am. J. Respir. Crit. Care Med. 1997 156 : 382 388.
97. Springall DR, Howarth PH, Counihan H et al. Endothelin immunoreactivity of airway epithelium in asthmatic patients. Lancet 1991 337 : 697 701.
98. Goldie RG, Henry PJ, Paterson JW et al. Contractile effects and receptor distributions for endothelin-1 (ET-1) in human and animal airways. Agents Actions Suppl. 1990 31 : 229 232.
99. Mattoli S, Soloperto M, Marini M et al. Levels of endothelin in the bronchoalveolar lavage fluid of patients with symptomatic asthma and reversible airflow obstruction. J. Allergy Clin. Immunol. 1991 88 : 376 384.
100. Aoki T, Kojima T, Ono A et al. Circulating endothelin-1 levels in patients with bronchial asthma. Ann. Allergy 1994 73 : 365 369.
101. DeNucci G, Thomas R, D'Orleans-Juste P et al. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium derived relaxing factor. Proc. Natl. Acad. Sci. USA 1988 85 : 9797 9800.
102. Hasunuma K, Rodman DM, O'Brien RF et al. Endothelin-1 causes pulmonary vasodilation in rats. Am. J. Physiol. 1990 259 : H48 54.
103. Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol. 2001 2 : 1 12.
104. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987 235 : 442 447.
105. Cao R, Bråkenhielm E, Pawliuk R et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat. Med. 2003 9 : 604 613.
106. Wang L, Kwak JH, Kim SI et al. Transforming growth factor-b1 stimulates vascular endothelial growth factor 164 via mitogen activated protein kinase kinase 3-p38α and p38δ mitogen-activated protein kinase-dependent pathway in murine mesangila cells. J. Biol. Chem. 2004 279 : 33213 33219.
107. Renner U, Lohrer P, Schaaf L et al. Transforming growth factor-b stimulates vascular endothelial growth factor production by folliculstellate pituitary cells. Endocrinology 2002 143 : 3759 3763.
108. Saito H, Tsujitani S, Oka S et al. The expression of transforming growth factor-beta-1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma. Cancer 1999 86 : 1455 1462.
109. Wen F, Liu X, Manda W et al. TH2-cytokine enhances and TGF-b-enhanced vascular endothelial growth factor production by cultured human airway smooth muscle cells is attenuated by IFN-γ and corticosteroids. J. Allergy Clin. Immunol. 2003 111 : 1307 1318.
110. Bussolino F, Mantovani A, Persico G. Molecular mechanism of blood vessel formation. Trends Biochem. Sci. 1997 22 : 251 256.
111. Lal BK, Varma S, Pappas PJ et al. VEGF increases permeability of the endothelial cell monolayer by activation of PKB/akt, endothelial nitric-oxide synthase, and MAP kinase pathways. Microvasc. Res. 2001 62 : 252 262.
112. Coomber BL. Cytoskeleton in TFG-b- and bFGF-modulated endothelial monolayer repair. Exp. Cell Res. 1991 194 : 42 7.
113. Hurst VI, Goldberg PL, Minnear FL et al. Rearrangement of adherens junctions by transforming growth factorb1: role of contraction. Am. J. Physiol. 1999 276.
114. Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation 2004 109 : 159 165.
115. Chetta A, Zanini A, Olivieri D. Therapeutic approach to vascular remodelling in asthma. Pulm. Pharmacol. Ther. 2007 20 : 1 8.
116. Hirata A, Ogawa S, Kometani T et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res. 2002 62 : 2554 2560.
117. Goldstein NI, Prewett M, Zuklys K et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumour xenograft model. Clin. Cancer Res. 1995 1 : 1311 1318.
118. Huang SM, Li J, Harari PM. Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. Mol. Cancer Ther. 2002 1 : 507 514.
119. Kim HS, Shin HS, Kwak HJ et al. Betacellulin induces angiogenesis through activation of mitogen-activated protein kinase and phosphatidylinositol 30-kinase in endothelial cell. FASEB J. 2003 17 : 318 320.
120. Baker CH, Solorzano CC, Fidler IJ. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res. 2002 62 : 1996 2003.
121. Okamura K, Morimoto A, Hamanaka R et al. A model system for tumour angiogenesis: involvement of transforming growth factor-a in tube formation of human microvascular endothelial cells induced by esophageal cancer cells. Biochem. Biophys. Res. Commun. 1992 186 : 1471 1479.
122. Goldman CK, Kim J, Wong WL et al. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol. Biol. Cell 1993 4 : 121 133.
123. Tello-Montoliu A, Patel JV, Lip GY. Angiogenin: a review of the pathophysiology and potential clinical applications. J. Thromb. Haemost. 2006 4 : 1864 1874.
124. Bond MD, Vallee BL. Isolation and sequencing of mouse angiogenin DNA. Biochem. Biophys. Res. Commun. 1990 171 : 988 995.
125. Bicknell R, Vallee BL. Angiogenin activates endothelial cell phospholipase C. Proc. Natl. Acad. Sci. USA 1988 85 : 5961 5965.
126. Liu S, Yu D, Xu ZP et al. Angiogenin activates Erk1/2 in human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun. 2001 287 : 305 310.
127. Moroianu J, Riordan JF. Nuclear translocation of angiogenin in proliferating endothelial cell is essential to its angiogenic activity. Proc. Natl. Acad. Sci. USA 1994 91 : 1677 1681.
128. Lee WW, Galbraith RM. The extracellular actin-scavenger system and actin toxicity. N. Engl. J. Med. 1992 326 : 1335 1341.
129. Hallahan TW, Shapiro R, Vallee BL. Dual site model for the organogenic activity of angiogenin. Proc. Natl. Acad. Sci. USA 1991 88 : 2222 2226.
130. Hu GF, Riordan JF. Angiogenin enhances actin acceleration of plasminogen activation. Biochem. Biophys. Res. Commun. 1993 197 : 682 687.
131. Lyons RM, Gentry LE, Purchio AF et al. Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin. J. Cell Biol. 1990 110 : 1361 1367.
132. Wilson JW. Vessels: new targets for asthma treatment. Thorax 2001 56 : 899 900.
133. Feltis BN, Wignarajah D, Reid DW et al. Effects of inhaled fluticasone on angiogenesis and vascular endothelial growth factor in asthma. Thorax 2007 62 : 314 319.
134. Knox AJ, Deacon K, Clifford R. Blanching the airways: steroid effects in asthma. Thorax 2007 62 : 283 285.
135. Bandi N, Kompella UB. Budesonide reduces vascular endothelial growth factor secretion and expression in airway (Calu-1) and alveolar (A549) epithelial cells. Eur. J. Pharmacol. 2001 425 : 109 116.
136. Horiuchi T, Weller PF. Expression of vascular endothelial growth factor by human eosinophila: up-regulation by granulocyte macrophage colony-stimulating factor and interleukin-5. Am. J. Respir. Cell Mol. Biol. 1997 17 : 70 7.
137. Nomura S, Kanazawa H, Hirata K et al. Relationship between vascular endothelial growth factor and angiopoietin-2 in asthmatics before and after inhaled beclomethasone therapy. J. Asthma 2005 42 : 141 146.
138. Hashimoto S, Gon Y, Matsumoto K et al. Inhalant Corticosteroids inhibit hyperosmolarity-induced, and cooling and rewarming-induced interleukin-8 and RANTES production by human bronchial epithelial cells. Am. J. Respir. Crit. Care Med. 2000 162 : 1075 1080.
139. Wilson SJ, Wallin A, Della-Cioppa G et al. Effects of budesonide and formoterol on NF-kappaB, adhesion molecules, and cytokines in asthma. Am. J. Respir. Crit. Care Med. 2001 164 : 1047 1052.
140. Hoshino S, Takahashi M, Takai Y et al. Inhaled corticosteroids decrease subepithelial collagen deposition by modulation of the balance between matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 expression in asthma. J. Allergy Clin. Immunol. 1999 104 : 356 363.
141. Van de Graaf EA, Out TA, Roos CM et al. Respiratory membrane permeability and bronchial hyperreactivity in patients with stable asthma. Effects of therapy with inhaled steroids. Am. Rev. Respir. Dis. 1991 143 : 362 368.
142. Nomura S, Kanazawa H, Asai K et al. Potential mechanisms of improvement of airway hyperresponsiveness by inhaled corticosteroid therapy in asthmatic patients. J. Asthma 2006 43 : 113 117.
143. Dente FL, Bancalari L, Bacci E et al. Effect of a single dose of salmeterol on the increase in airway eosinophils induced by allergen challenge in asthmatic subjects. Thorax 1999 54 : 622 624.
144. Li X, Ward C, Thien F et al. An antiinflammatory effect of salmeterol, a long-acting beta(2) agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma. Am. J. Respir. Crit. Care Med. 1999 160 : 1493 1499.
145. Korn SH, Jerre A, Brattsand R. Effects of formoterol and budesonide on GM-CSF and IL-8 secretion by triggered human bronchial epithelial cells. Eur. Respir. J. 2001 17 : 1070 1077.
146. Reid DW, Ward C, Wang N et al. Possible anti-inflammatory effect of salmeterol against interleukin-8 and neutrophil activation in asthma in vivo. Eur. Respir. J. 2003 21 : 994 999.
147. Proud D, Reynolds CJ, Lichtenstein LM et al. Intranasal salmeterol inhibits allergen-induced vascular permeability but not mast cell activation or cellular infiltration. Clin. Exp. Allergy 1998 28 : 868 875.
148. Greiff L, Wollmer P, Andersson M et al. Effects of formoterol on histamine induced plasma exudation in induced sputum from normal subjects. Thorax 1998 53 : 1010 1013.
149. Bolton PB, McDonald DM. Salmeterol reduces early and late phase plasma leakage and leucocyte adhesion in rat airways. Am. J. Respir. Crit. Care Med. 1997 155 : 1428 1435.
150. Baluk P, McDonald DM. The β2-adrenergic receptor agonist formoterol reduces microvascular leakage by inhibiting endothelial gap formation. Am. J. Physiol. 1994 266 : L461 8.
151. Barnes PJ, Chung KF, Page CP. Inflammatory mediators of asthma: an update. Pharmacol. Rev. 1998 50 : 515 596.
152. Sawaoka H, Tsuji S, Tsujii M et al. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab. Investig. 1999 79 : 1469 1477.
153. Hsu AL, Ching TT, Wang DS et al. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J. Biol. Chem. 2000 275 : 11397 11403.
154. Wei D, Wang L, He Y et al. Celecoxib inhibits vascular endothelial growth factor expression by targeting Sp1 transcription factor and reduces human pancreatic cancer angiogenesis and metastasis. Proc. Am. Assoc. Cancer Res. 2003 44 : 633 (abstr2774).
155. Ma L, del Soldato P, Wallace JL. Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: shifting the angiogenic balance. Proc. Natl. Acad. Sci. USA 2002 99 : 13243 13247.
156. Wilkinson-Berka JL, Alousis NS, Kelly DJ et al. COX-2 inhibition and retinal angiogenesis in a mouse model of retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. 2003 44 : 974 979.
157. Stocks J, Bradbury D, Corbett L et al. Cytokines upregulate vascular endothelial growth factor secretion by human airway smooth muscle cells: Role of endogenous prostanoids. FEBS Lett. 2005 579 : 2551 2556.
158. Ruckman J, Green LS, Beeson J et al. F'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J. Biol. Chem. 1998 274 : 20556 20567.
159. Chen Y, Wiesmann C, Fuh G et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J. Mol. Biol. 1999 293 : 865 881.
160. Gragoudas ES, Adamis AP, Cunningham ET et al. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 2004 351 : 2805 2816.
161. Smith JK, Mamoon NM, Duhe RJ. Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy. Oncol. Res. 2004 14 : 175 225.
162. Wedge SR, Ogilvie DJ, Dukes M et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 2002 62 : 4645 4655.
163. Drevs J, Esser N, Konerding MA et al. Effect of ZD6474, a VEGF receptor tyrosine kinase inhibitor, on primary tumor growth, metastasis, vessel density and microvascular architecture in murine renal cell carcinoma. Proc. Am. Assoc. Cancer Res. 2002 43 : Abs 1082.
164. Wood JM, Bold G, Buchdunger E et al. PTK787/ZK222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 2000 60 : 2178 2189.
165. Lee YC, Kwak YG, Song CH. Contribution of vascular endothelial growth factor to airway hyperresponsiveness and inflammation in a murine model of toluene diisocyanate-induced asthma. J. Immunol. 2002 168 : 3595 3600.
166. Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 2004 362 : 841 844.
167. Ferrara N, Hillan KJ, Gerber HP et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 2004 3 : 391 400.
168. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004 350 : 2335 2342.
169. Suri C, McClain J, Thurston G et al. Increased vascularization in mice over expressing angiopoietin-1. Science 1998 282 : 468 471.
170. Thurston G, Suri C, Smith K et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 1999 286 : 2511 2514.
171. Cho CH, Kammerer RA, Lee HJ et al. COMP-Ang1: a designed angiopoietin-1 variant with nonleaky angiogenic activity. Proc. Natl. Acad. Sci. USA 2004 101 : 5547 5552.
172. Khor YH, Teoh AK, Lam SM et al. Increased vascular permeability precedes cellular inflammation as asthma control deteriorates. Clin. Exp. Allergy 2009 39 : 1659 1667.